Familial Hypertrophic Cardiomyopathy: Diagnosis and Management
Vascular Health and Risk Management · 2023-04 · Volume 19 · 211-221
DOI: 10.2147/vhrm.s365001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vascular Health and Risk Management, 2023-04. Verfasst von Michael J Litt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Familial, Cardiomyopathy, Hypertrophic, Defibrillators, Implantable. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
ORCID-Profile: Nosheen Reza
Zitieren
APA
Litt, M. J., Ali, A., & Reza, N. (2023). Familial Hypertrophic Cardiomyopathy: Diagnosis and Management. Vascular Health and Risk Management, Volume 19, 211-221. https://doi.org/10.2147/vhrm.s365001
Vancouver
Litt MJ, Ali A, Reza N. Familial Hypertrophic Cardiomyopathy: Diagnosis and Management. Vascular Health and Risk Management. 2023;Volume 19:211-221. doi:10.2147/vhrm.s365001
BibTeX
@article{Litt2023,
author = {Litt, Michael J and Ali, Ayan and Reza, Nosheen},
title = {Familial Hypertrophic Cardiomyopathy: Diagnosis and Management},
journal = {Vascular Health and Risk Management},
year = {2023},
volume = {Volume 19},
pages = {211--221},
doi = {10.2147/vhrm.s365001}
}
EUVIMED